Novel Ligands for Cell Selective Gene Silencing
Vadim Dudkin, PhD, Founding Chief Technology Officer, Soufflé Therapeutics
#novelligands #selectivegenes #genometherapy #oligonucleotidediscovery #siRNAtherapeutics #targeteddelivery
Why this is critically important to the oligonucleotide / targeted therapeutics industry?
Targeted gene silencing is a cornerstone of precision therapeutics, but how can you utilise platforms to further your therapeutics quickly, efficiently, and compliantly. In this keynote, Dr. Dudkin explores Soufflé Therapeutics’ proprietary discovery platform for identifying cell- and tissue-specific ligands. These ligands, conjugated to siRNA, allow selective silencing in skeletal muscle and heart cells while sparing off-target tissues.
Designed for those working in oligonucleotide discovery, siRNA therapeutics, and targeted delivery, this session will provide you with the knowledge of a platform approach to overcome one of the biggest challenges in gene therapy – precise, tissue-specific delivery. You will walk away with an understanding on how these strategies underpin the advancement of the field, to aid in safer and more effective cell-selective therapies.
How will it help your career?
This is your opportunity to gain practical knowledge in translating ligand discovery into targeted genetic medicines, including identifying receptors and ligands for tissue-specific delivery, designing conjugated siRNA molecules for selective gene silencing, and applying platform-based approaches to advance precision therapeutics pipelines effectively. You will understand how to overcome delivery challenges, refine your targeting strategies, and accelerate development for the next generation of gene silencing therapies.
Ideal for those working in research and development, oligonucleotide chemistry, therapeutic delivery, and translational medicine.
Platform-based approaches may be the key to your next breakthrough. Can you afford to miss out on this critical discussion?
